Potent Inhibition of Mandelate Racemase by a Fluorinated Substrate-Product Analogue with a Novel Binding Mode by Nagar, Mitesh et al.
Marquette University 
e-Publications@Marquette 
Biological Sciences Faculty Research and 
Publications Biological Sciences, Department of 
2-25-2014 
Potent Inhibition of Mandelate Racemase by a Fluorinated 
Substrate-Product Analogue with a Novel Binding Mode 
Mitesh Nagar 
Dalhousie University 
Adam D. Lietzan 
Marquette University, adam.lietzan@marquette.edu 
Martin St. Maurice 
Marquette University, martin.stmaurice@marquette.edu 
Stephen L. Bearne 
Dalhousie University 
Follow this and additional works at: https://epublications.marquette.edu/bio_fac 
 Part of the Biology Commons 
Recommended Citation 
Nagar, Mitesh; Lietzan, Adam D.; Maurice, Martin St.; and Bearne, Stephen L., "Potent Inhibition of 
Mandelate Racemase by a Fluorinated Substrate-Product Analogue with a Novel Binding Mode" (2014). 






Biological Sciences Faculty Research and Publications/College of Arts and 
Sciences 
 
This paper is NOT THE PUBLISHED VERSION; but the author’s final, peer-reviewed manuscript. The 
published version may be accessed by following the link in the citation below. 
 
Biochemistry, Vol. 53, No. 7 (25 February 2014): 1169–1178. DOI. This article is © American Chemical 
Society Publications and permission has been granted for this version to appear in e-
Publications@Marquette. American Chemical Society Publications does not grant permission for this 
article to be further copied/distributed or hosted elsewhere without the express permission from 
American Chemical Society Publications.  
 
Potent Inhibition of Mandelate Racemase by 
a Fluorinated Substrate-Product Analogue 
with a Novel Binding Mode 
 
Mitesh Nagar 
Department of Biochemistry and Molecular Biology, Dalhousie University, Halifax, Nova Scotia, Canada 
Adam D. Lietzan 
Department of Biological Sciences, Marquette University, Milwaukee, Wisconsin 
Martin St. Maurice 
Department of Biological Sciences, Marquette University, Milwaukee, Wisconsin 
Stephen L. Bearne 
Department of Biochemistry and Molecular Biology, Dalhousie University, Halifax, Nova Scotia, Canada 








Mandelate racemase (MR) from Pseudomonas putida catalyzes the Mg2+-dependent 1,1-proton transfer that 
interconverts the enantiomers of mandelate. Because trifluorolactate is also a substrate of MR, we anticipated 
that replacing the phenyl rings of the competitive, substrate-product analogue inhibitor benzilate (Ki = 0.7 mM) 
with trifluoromethyl groups might furnish an inhibitor. Surprisingly, the substrate-product analogue 3,3,3-
trifluoro-2-hydroxy-2-(trifluoromethyl)propanoate (TFHTP) was a potent competitive inhibitor [Ki = 27 ± 4 μM; 
cf. Km = 1.2 mM for both (R)-mandelate and (R)-trifluorolactate]. To understand the origins of this high binding 
affinity, we determined the X-ray crystal structure of the MR–TFHTP complex to 1.68 Å resolution. Rather than 
chelating the active site Mg2+ with its glycolate moiety, like other ground state analogues, TFHTP exhibited a 
novel binding mode with the two trifluoromethyl groups closely packed against the 20s loop and the carboxylate 
bridging the two active site Brønsted acid–base catalysts Lys 166 and His 297. Recognizing that positioning a 
carboxylate between the Brønsted acid–base catalysts could yield an inhibitor, we showed that tartronate was a 
competitive inhibitor of MR (Ki = 1.8 ± 0.1 mM). The X-ray crystal structure of the MR–tartronate complex (1.80 
Å resolution) revealed that the glycolate moiety of tartronate chelated the Mg2+ and that the carboxylate 
bridged Lys 166 and His 297. Models of tartronate in monomers A and B of the crystal structure mimicked the 
binding orientations of (S)-mandelate and that anticipated for (R)-mandelate, respectively. For the latter 
monomer, the 20s loop appeared to be disordered, as it also did in the X-ray structure of the MR triple mutant 
(C92S/C264S/K166C) complexed with benzilate, which was determined to 1.89 Å resolution. These observations 
indicate that the 20s loop likely undergoes a significant conformational change upon binding (R)-mandelate. In 
general, our observations suggest that inhibitors of other enolase superfamily enzymes may be designed to 
capitalize on the recognition of the active site Brønsted acid–base catalysts as binding determinants. 
Mandelate racemase (MR, EC 5.1.2.2) from Pseudomonas putida catalyzes the Mg2+-dependent 1,1-proton 
transfer that interconverts the enantiomers of mandelate via a two-base mechanism with His 297 and Lys 166 
abstracting the α-proton from (R)-mandelate and (S)-mandelate, respectively, as shown in Scheme 1.(1) MR is 
very proficient at discriminating between the substrate in the ground state and the altered substrate in the 
transition state, binding the latter species with an association constant equal to 5 × 1018 M–1 and stabilizing the 
transition state of the reaction by 26 kcal/mol.(2, 3) Consequently, MR has been studied as a paradigm for 
enzymes that catalyze rapid carbon–hydrogen bond cleavage of carbon acids with relatively high 
pKa values.(1) Recently, we demonstrated that β,γ-unsaturation is not a necessary requirement for catalysis and 
that MR is capable of catalyzing the racemization of the enantiomers of 3,3,3-trifluorolactate (TFL). 
Although kcat for this substrate was reduced by ∼100-fold relative to that of mandelate as a substrate, the values 
of Km were 1.7 and 1.2 mM for (S)- and (R)-TFL, respectively, similar to the corresponding values of 1.2 and 1.0 
mM observed for (R)- and (S)-mandelate, respectively.(4) The fact that MR bound TFL with an affinity similar to 
that exhibited for mandelate was unexpected considering that MR binds lactate with low affinity (Ki ≈ 30 
mM).(5) Indeed, the binding affinity that MR exhibits for TFL exceeds that expected on the basis of hydrophobic 
effects alone.(4) 
 
Scheme 1. Reaction Catalyzed by Mandelate Racemase (MR) and Structures of Inhibitors Discussed in the Text 
 
Previously, we observed that the substrate-product analogue benzilate (Ki = 0.67 mM) is a competitive inhibitor 
of MR, binding with an affinity that is similar to that exhibited for mandelate.(6) Consequently, we rationalized 
that an inhibitor of MR might be generated by replacing the phenyl rings of benzilate with trifluoromethyl 
groups. Herein, we describe the potent inhibition of MR by the substrate-product analogue 3,3,3-trifluoro-2-
hydroxy-2-(trifluoromethyl)propanoate (TFHTP). Surprisingly, the X-ray crystal structure of MR with bound 
TFHTP reveals that the inhibitor is bound with an orientation that differs markedly from the binding orientation 
observed previously for the substrate,(7) analogues of the substrate,(8-11) and intermediate 
analogues.(12) Interestingly, the higher binding affinity of TFHTP arises, in part, because the carboxylate group 
forms a salt bridge between the Brønsted acid–base catalysts His 297 and Lys 166. Recognition of this novel 
binding mode led to our subsequent identification of tartronic acid as an inhibitor of MR. We show that the 
glycolate moiety of tartronic acid chelates the Mg2+ ion within the active site in a manner similar to that of 
mandelate, while the second carboxylate bridges the two Brønsted acid–base catalysts in a manner similar to 
that of TFHTP. 
Materials and Methods 
General 
Tartronic acid was purchased from Alfa Aesar (Ward Hill, MA). (R)-Mandelic acid, α-hydroxyisobutyric acid, 3,3,3-
trifluoro-2-hydroxy-2-(trifluoromethyl)propanoic acid, and all other reagents, unless mentioned otherwise, were 
purchased from Sigma-Aldrich Canada Ltd. (Oakville, ON). Nuclear magnetic resonance (NMR) analyses were 
conducted at the Nuclear Magnetic Resonance Research Resource (NMR-3) using either a Brüker/Tecmag AC-
250 spectrometer, a Brüker AV-300 spectrometer, or a Brüker AV-500 spectrometer. Chemical shifts (δ) for 
proton (1H), carbon (13C), and phosphorous (31P) spectra are reported in parts per million relative to the HOD 
signal for spectra obtained in D2O. High-resolution (HR) electrospray ionization (ESI) mass spectra (MS) were 
recorded using a Brüker microTOF Focus orthogonal ESI-TOF mass spectrometer instrument operating in either 
positive or negative ion mode. Circular dichroism (CD) assays were conducted using a JASCO (Easton, MD) J-810 
spectropolarimeter with a jacketed cell holder. Melting points are uncorrected. 
(R,S)-1-Hydroxy-2,2,2-trifluoroethylphosphonate (TFHEP) 
The ethyl groups were removed from diethyl 1-hydroxy-2,2,2-trifluoroethylphosphonate by treatment with 
trimethylsilylbromide using a procedure similar to that described by Freeman et al.(13) Diethyl 1-hydroxy-2,2,2-
trifluoroethylphosphonate (1.0 g, 4.24 mmol) was dissolved in 10 mL of dry acetonitrile. Trimethylsilylbromide 
(2.63 mL, 20.4 mmol, 4.8 equiv) was added dropwise to the solution. The solution was refluxed for 1 h under an 
atmosphere of argon, and the solvent was removed using rotary evaporation under reduced pressure to yield a 
slightly yellow liquid. Dioxane (3.4 mL), water (3.4 mL), and cyclohexylamine (1.6 mL) were added, and the 
solution was stirred for 1 h. After removal of the solvent using rotary evaporation, a white powder remained. 
This was dissolved in water (16 mL), and the solution was filtered. Acetone (150 mL) was added, and a white 
precipitate, the cyclohexylamine salt, formed upon sitting.(14) After being cooled for 1 h at 4 °C, the precipitate 
was collected using suction filtration. The cyclohexylamine salt was then converted to the sodium salt by passing 
it through a column containing AG 50W-X8 (Na+ form). The eluent was collected, and lyophilization yielded a 
white powder (0.85 g, 90%): mp 238–241 °C (crystal became opaque at 90 °C); 1H NMR (500 MHz, D2O) δ 4.12 
(m); 13C NMR (63 MHz, D2O, 1H-decoupled) δ 67.60 (dq, 1JC,P = 151.3 Hz, 2JC,F = 30.6 Hz, CH), 124.61 (qd, 1JC,F = 
280.9 Hz, 2JC,P = 5.6 Hz, CF3); 31P NMR (101 MHz, D2O, 1H-decoupled) δ 11.88 (q, 3JF,P = 7.43 Hz); 19F NMR (235 
MHz, D2O) δ −71.08 (dd, 3JF,H = 15.30 Hz, 3JF,P = 7.43 Hz); HRMS (ESI–) m/z calcd for C2H3F3O4P [M – H]− 178.9721, 
found 178.9735. 
(R,S)-1-Hydroxyethylphosphonate (1-HEP) 
Synthesis of dimethyl 1-hydroxyethylphosphonate was conducted as described by Chen et al.(15) Dimethyl 
phosphate (1.10 g, 10 mmol) and acetaldehyde (0.44 g, 10 mmol) were stirred together for 10 min at room 
temperature, followed by addition of potassium fluoride and basic alumina (1:1 mass ratio, 3 g each). After the 
mixture had been stirred for an additional 30 min, methylene chloride (15 mL) was added and the resulting 
suspension was filtered. From the filtrate, methylene chloride was evaporated under reduced pressure, leaving 
0.68 g of dimethyl 1-hydroxyethylphosphonate as a viscous yellow liquid. The methyl groups were removed 
from dimethyl 1-hydroxyethylphosphonate by treatment with trimethylsilylbromide using a procedure similar to 
that described by Freeman et al.(13) Dimethyl 1-hydroxyethylphosphonate (0.49 g, 3.2 mmol) was dissolved in 
dry acetonitrile (10 mL). Trimethylsilylbromide (2.26 mL, 17.5 mmol, 5.0 equiv) was added dropwise to the 
solution. The solution was refluxed for 1 h under an atmosphere of argon, and the solvent was removed using 
rotary evaporation under reduced pressure to yield a slightly yellow liquid. Dioxane (3.4 mL), water (3.4 mL), and 
cyclohexylamine (1.6 mL) were added, and the solution was stirred for 1 h at room temperature. After removal 
of the solvent using rotary evaporation, a slightly yellow liquid was obtained. This was dissolved in water (16 
mL), and then acetone (150–250 mL) was added until the cyclohexylamine salt formed as a white precipitate. 
After being cooled overnight at 4 °C, the precipitate was collected using suction filtration. The cyclohexylamine 
salt was then converted to the sodium salt by passing it through a column containing AG 50W-X8 (Na+ form). 
Fractions containing phosphonate were pooled and lyophilized to obtain the sodium salt of 1-
hydroxyethylphosphonate as a white powder (0.224 g, 41%): mp 223–225 °C; 1H NMR (D2O, 500 MHz) δ 1.23 
(dd, 3JH,H = 7.1 Hz, 3JH,P = 15.9 Hz, 3H, CH3), 3.74 (dq, 3JH,H = 7.1 Hz, 2JH,P = 5.9 Hz, 1H, OCHP); 13C NMR (D2O, 126 
MHz, 1H-decoupled) δ 17.10 (CH3), 64.72 (d, 1JC,P = 157.9 Hz, OCHP); 31P NMR (D2O, 202 MHz, 1H-decoupled) δ 
20.94; 31P NMR (D2O, 202 MHz, 1H-coupled) δ 20.94 (dq, 2JH,P = 5.91 Hz, 3JH,P = 15.90 Hz); HRMS (ESI+) m/z calcd 
for C2H6Na2O4P [M + H]+ 170.9799, found 170.9800. 
Concentration Correction for TFHEP and 1-HEP 
1H NMR spectroscopy was used to correct for the presence of waters of hydration and sodium ion stoichiometry 
and thereby permit accurate estimation of the concentration of TFHEP and 1-HEP in solution. Equimolar 
solutions (∼20 mM based on the theoretical molecular weight) of 1-HEP (170.01 g/mol) or TFHEP (223.98 g/mol) 
and sodium acetate were prepared in 5 mL of D2O. 1H NMR spectra for these solutions were obtained, and 
integrated signal intensities corresponding to the α-H and α-CH3 of 1-HEP and the α-H of TFHEP were calculated 
with reference to the signal intensities of the methyl protons of the sodium acetate internal standard. The actual 
concentrations of 1-HEP and TFHEP were then calculated from the ratio of signal intensities and the known 
concentration of sodium acetate. 
Site-Directed Mutagenesis 
The C92S/C264S/K166C triple mutant of MR (tmMR) was constructed by performing three rounds of polymerase 
chain reaction-based site-directed mutagenesis using the QuikChange Site-Directed Mutagenesis Kit (Stratgene, 
La Jolla, CA) and following the protocols described by the manufacturer. The pET52b(+)-wtMR plasmid(16) was 
used as a template to create the C264S MR mutant plasmid, which was then used as a template in the next 
round of site-directed mutagenesis to create a double-mutant C92S/C264S MR plasmid. Finally, the K166C 
mutation was introduced to generate tmMR using the double-mutant plasmid as the template. Reactions were 
conducted using PfuTurbo DNA polymerase (Bio Basic Inc., Markham, ON). The forward (F) and reverse (R) 
synthetic deoxyoligonucleotide primers used to construct the mutants were 5′-
CGCAAAACGCTTCAGCCTGGCAGGTTATACGGG-3′ (F, C92S), 5′-CCCGTATAACCTGCCAGGCTGAAGCGTTTTGCG-3′ (R, 
C92S), 5′-GCATTGAGCATCGGTGCAAGCCGGTTGGCTATGCC-3′ (F, C264S), 5′-
GGCATAGCCAACCGGCTTGCACCGATGCTCAATGC-3′ (R, C264S), 5′-GCGGTTAAGACCTGCATCGGCTATCCGGC-3′ (F, 
K166C), and 5′-GCCGGATAGCCGATGCAGGTCTTAACCGC-3′ (R, K166C). The codons specifying the relevant amino 
acids are underlined, and the altered bases are shown in bold. Potential mutant plasmids were used to 
transform competent Escherichia coli DH5α cells. DH5α cells were used for plasmid maintenance and for all 
sequencing reactions. After each round of site-directed mutagenesis, the mutant open reading frame was 
sequenced using commercial automated DNA sequencing (Robarts Research Institute, London, ON) to ensure 
that no other alterations of the nucleotide sequence had been introduced. For X-ray crystallography studies, 
tmMR was overexpressed in and purified from E. coli BL21(DE3) cells as described previously for wild-type 
MR.(12) Replacement of Cys 92 and Cys 264 with Ser residues did not significantly alter the activity of the 
enzyme (M. Nagar and S. L. Bearne, unpublished observations). 
Enzyme Purification 
Recombinant MR from P. putida was overproduced in and purified from E. coli BL21(DE3) cells transformed with 
the pET-52b(+)-wtMR plasmid, a pET-52b(+) plasmid (Novagen, Madison, WI) containing the MR open reading 
frame.(16) This construct encodes the MR gene product (MASWSHPQFEKGALEVLFQGPGYHM1...MR) as a fusion 
protein with an N-terminal StrepII tag (underlined; M1 represents the first amino acid of wild-type MR). The 
enzyme was purified by affinity chromatography using Strep-Tactin Superflow resin (IBA GmbH, Göttingen, 
Germany) as described previously.(16) Upon elution from the column, the enzyme was dialyzed against storage 
buffer {HEPES buffer (100 mM, pH 7.5) containing MgCl2 (3.3 mM), NaCl (200 mM), and glycerol [10% (v/v)]} and 
stored at −20 °C. The purity of the enzyme preparation (≥99%) was checked using 12% sodium dodecyl sulfate–
polyacrylamide gel electrophoresis. The tag was not removed from the enzyme. 
Enzyme Assays 
MR activity was assayed using a CD-based assay by following the change in ellipticity of mandelate at 262 nm 
with a 1 cm light path (unless otherwise indicated) as described by Sharp et al.(17) All kinetic assays, including 
inhibition experiments with TFHEP, 1-HEP, TFHTP, tartronate, and α-hydroxyisobutyrate, were conducted at 25 
°C in Na+-HEPES buffer (0.1 M, pH 7.5) containing MgCl2 (3.3 mM) and bovine serum albumin (BSA, 0.005%). The 
concentration of (R)-mandelate for assays ranged from 0.25 to 20.0 mM. The concentrations of the inhibitors 
and MR used were as follows: 0.81, 1.62, and 3.24 mM TFHEP (150.72 ng/mL; using a cuvette with a 0.5 cm light 
path for 3.24 mM TFHEP), 16.37, 32.74, and 65.49 mM 1-HEP (122.4 ng/mL; using a cuvette with a 0.5 cm light 
path), 0.02, 0.05, and 0.10 mM TFHTP (129.8 ng/mL), 0.75, 1.50, and 3.00 mM tartronate (131.45 ng/mL), and 
3.5, 7.0, and 14.0 mM α-hydroxyisobutyrate (141.55 ng/mL; using a cuvette with a 0.5 cm light path). The 
apparent kinetic constants Vmax and Km were determined by fitting the initial velocity data to eq 1 using 






Competitive inhibition constants (Ki) were determined from plots of the apparent Km/Vmax values versus inhibitor 









All kinetic parameters were determined in triplicate, and average values are reported. The reported errors are 
standard deviations. The concentration of wild-type MR was determined from its absorbance at 280 nm using an 
extinction coefficient of 53400 M–1 cm–1, which was calculated using the ProtParam tool available on the ExPASy 
server (http://web.expasy.org/protparam).(19) 
Protein Crystallization 
Crystals were grown by the hanging-drop vapor diffusion method against a reservoir volume of 500 μL. The 
protein solution and reservoir solution were mixed in a 1:1 ratio to a final volume of 4 μL. Crystals grew 
spontaneously at 21 °C and ∼50% humidity. 
Cocrystallization of MR with TFHTP 
For the MR crystals grown in the presence of TFHTP, the reservoir solution consisted of PEG 1500 [20% (w/v)], 
glycine (120 mM), KNO3 (70 mM), and Tris-HCl buffer (100 mM, pH 8.0). The protein solution consisted of 5.9 
mg/mL MR purified as described above, MgCl2 (3.3 mM), TFHTP (1 mM), and HEPES buffer (50 mM, pH 7.5). The 
resulting cubelike crystals (∼100 μm × 60 μm × 50 μm) grew to full size within 10–20 days. Crystals were 
harvested and transferred to a synthetic stabilizing solution consisting of PEG 1500 [24% (w/v)], glycine (132 
mM), KNO3 (70 mM), TFHTP (1 mM), and Tris-HCl buffer (80 mM, pH 8.0). These stabilized crystals were 
equilibrated in the synthetic stabilizing solution for 5–10 min and then were transferred directly to a 
cryoprotectant solution consisting of PEG 1500 [40% (w/v)], glycine (138 mM), KNO3 (70 mM), TFHTP (1 mM), 
and Tris-HCl buffer (100 mM, pH 8.0). The cryoprotected crystals were flash-cooled in a nitrogen gas stream at 
100 K. 
Cocrystallization of MR with Tartronate 
For the MR crystals grown in the presence of tartronate, the reservoir solution consisted of PEG 1500 [14% 
(w/v)], glycine (100 mM), and triethanolamine buffer (100 mM, pH 8.5). The protein solution consisted of 6.0 
mg/mL MR purified as described above, MgCl2 (3.3 mM), sodium tartronate (20 mM), and HEPES buffer (50 mM, 
pH 7.5). The resulting cubelike crystals (∼70 μm × 70 μm × 50 μm) grew to full size within 20–30 days. 
Approximately 50 days after crystallization had been initiated, the crystals were harvested and transferred to a 
synthetic stabilizing solution consisting of PEG 1500 [19% (w/v)], glycine (110 mM), sodium tartronate (20 mM, 
pH 7.5), and triethanolamine buffer (100 mM, pH 8.5). These stabilized crystals were equilibrated in the 
synthetic stabilizing solution for 5–10 min and then were transferred directly to a cryoprotectant solution 
consisting of PEG 1500 [39.5% (w/v)], glycine (110 mM), sodium tartronate (20 mM), and triethanolamine buffer 
(100 mM, pH 8.5). After being equilibrated in the cryoprotectant solution for 7 min, the crystals were flash-
cooled in a nitrogen gas stream at 100 K. 
Cocrystallization of tmMR with Benzilate 
Crystals of the MR triple mutant (C92S/C264S/K166C, tmMR) were grown in the presence of benzilate. The 
reservoir solution consisted of PEG 1500 [15% (w/v)], glycine (150 mM), NaCl (50 mM), and HEPES buffer (100 
mM, pH 7.5), and the protein solution consisted of 6.6 mg/mL tmMR purified as described above, MgCl2 (3.3 
mM), benzilate (20 mM), and HEPES buffer (50 mM, pH 7.5). The resulting cubelike crystals (∼160 μm × 90 μm × 
120 μm) grew to full size within 10–20 days. Crystals were harvested and transferred directly to a synthetic 
stabilizing solution consisting of PEG 1500 [24% (w/v)], glycine (165 mM), sodium tartronate (20 mM), NaCl (50 
mM), and HEPES buffer (80 mM, pH 7.5). These stabilized crystals were subsequently transferred to a solution 
containing PEG 1500 [42% (w/v)], glycine (175 mM), benzilate (20 mM), NaCl (60 mM), and HEPES buffer (100 
mM, pH 7.5), incubated for 5 min, and then flash-cooled in a nitrogen gas stream at 100 K. 
Data Collection, Structure Determination, and Refinement 
X-ray diffraction data for MR cocrystallized with tartronate were collected at Advanced Photon Source (APS) 
beamline LS-CAT-21-ID-G on a Rayonix MarMosaic 300 CCD detector, with an X-ray wavelength of 0.979 Å. X-ray 
diffraction data for MR cocrystallized with TFHTP were collected at APS beamline LS-CAT-21-ID-D on a Rayonix 
MarMosaic 300 CCD detector, with an X-ray wavelength of 1.13 Å. X-ray diffraction data for tmMR cocrystallized 
with benzilate were collected at APS beamline LS-CAT-21-ID-F on a Rayonix MarMosaic 225 CCD detector, with 
an X-ray wavelength of 0.979 Å. Diffraction images were processed using HKL2000.(20) The structures were 
determined by molecular replacement using the wild-type MR enzyme [Protein Data Bank (PDB) entry 2MNR] as 
the search model with Phaser.(21) The molecular replacement models were extended by several rounds of 
manual model building with COOT(22) and refinement with REFMAC(23) using a geometric/X-ray weighting term 
of 0.2. Noncrystallographic restraints between each monomer were applied for the first round of refinement but 
were relieved for subsequent rounds. Water molecules were added to the model in COOT with subsequent 
manual verification. Ligand coordinates for TFHTP were generated and optimized for structure refinement using 
eLBOW (electronic ligand building and optimization workbench).(24) Data collection and processing statistics are 
listed in Table 1. 
Table 1. Data Collection and Refinement Statisticsa 
  MR and tartronate MR and TFHTP tmMR and benzilate 
PDB entry 4M6U 4FP1 4HNC 
space group I422 I422 I422 
cell dimensions       
a, b, c (Å) 149, 149, 178 149, 149, 170 149, 149, 170 
α, β, γ (deg) 90, 90, 90 90, 90, 90 90, 90, 90 
resolution range (Å) 50.0–1.80 (1.83–1.80) 50.0–1.68 (1.71–1.68) 50.0–1.89 (1.92–1.89) 
redundancy 10.1 (8.7) 7.5 (5.6) 7.6 (5.5) 
completeness (%) 98.8 (99.8) 99.9 (99.3) 99.5 (98.9) 
no. of unique reflections 90212 107280 75403 
Rmerge (%) 7.3 (37.6) 7.7 (39.8) 7.6 (40.0) 
average I/σ 29.5 (5.0) 24.2 (4.5) 21.5 (3.4) 
Refinement    
resolution range (Å) 32.38–1.80 (1.85–1.80) 50.0–1.68 (1.72–1.68) 50.0–1.89 (1.94–1.89) 
Rcryst 0.147 (0.200) 0.169 (0.209) 0.170 (0.207) 
Rfree 0.171 (0.264) 0.193 (0.233) 0.198 (0.228) 
no. of protein atoms 5522 5974 5912 
no. of water molecules 637 445 504 
Wilson B value (Å2) 13.6 16.5 16.8 
average B factor (Å2)       
protein 19.7 16.0 17.2 
ligands 23.2 31.6 18.9 
Mg2+ 10.4 15.3 12.8 
solvent 28.8 23.8 25.6 
Ramachandran plot (%)       
most favored 90.8 90.7 90.9 
additionally allowed 8.4 8.7 8.4 
generously allowed 0.3 0.3 0.3 
disallowed 0.5 0.3 0.3 
root-mean-square deviation       
bond lengths (Å) 0.017 0.014 0.013 
bond angles (deg) 1.754 1.553 1.460 
aValues in parentheses are for the highest-resolution bin. 
Results and Discussion 
Inhibition by Ground State Analogues 
MR binds the enantiomers of mandelate and TFL with similar affinities (Table 2). However, the enzyme binds the 
enantiomers of lactate with approximately 23-fold less affinity than it exhibits for mandelate and TFL. This 
observation indicates that the trifluoromethyl group on the glycolate moiety contributes an additional ∼1.8 
kcal/mol to the free energy of binding relative to the methyl group. On the basis of the similar binding affinities 
that MR exhibits for mandelate and TFL, it appears that the binding determinants within the hydrophobic pocket 
of MR’s active site bind the phenyl ring of mandelate and the trifluoromethyl group of TFL with approximately 
equal affinity. Because MR binds the substrate-product analogue benzilate with an affinity that is similar to that 
exhibited for mandelate, we hypothesized that MR should bind TFHTP with similar affinity. To our surprise, MR 
bound TFHTP with an affinity (Ki = 27 μM) that exceeded that exhibited for mandelate and TFL by ∼54-fold 
(Table 2). The corresponding nonfluorinated analogue, α-hydroxyisobutyrate, however, was bound only weakly 
by MR (Ki = 5.5 mM), indicating that the presence of the six fluorine atoms in TFHTP increased the binding 
affinity by 204-fold and contributed an additional 3.1 kcal/mol to the free energy of binding. TFHTP is the most 
potent ground state analogue inhibitor of MR reported to date, binding with an affinity that is only slightly lower 
than those reported for the binding of the transition state/intermediate analogues (R,S)-α-
hydroxybenzylphosphonate (Ki = 4.7 μM),(25) benzohydroxamate (BzH; Ki = 9.3 μM),(25)N-hydroxyformanilide 
(Ki = 2.8 μM),(26) and Cupferron (Ki = 2.7 μM).(26) 
Table 2. Binding Constants for Substrates, Ground State Analogues, and Transition State Analogues 
R1R2R3COH     
R1 R2 R3 ligand Ki (mM)a 
Substrates and Substrate 
Analogues 
    
-C6H5 -H -COO– (R)-mandelate 1.2 ± 0.2b 
      (S)-mandelate 1.0 ± 0.1b 
-CF3 -H -COO– (R)-trifluorolactate [(R)-TFL] 1.2 ± 0.2b 
      (S)-trifluorolactate [(S)-TFL] 1.74 ± 0.08b 
-COO– -H -COO– tartronate 1.8 ± 0.1 
-CH3 -H -COO– (R)-lactate 32.0 ± 1.4c 
      (S)-lactate 26.1 ± 3.1c 
Substrate-Product Analogues     
-C6H5 -C6H5 -COO– benzilate 0.67 ± 0.12d 
-CF3 -CF3 -COO– 3,3,3-trifluoro-2-hydroxy-2-
(trifluoromethyl)propanoate 
(TFHTP) 
0.027 ± 0.004 
-CH3 -CH3 -COO– α-hydroxyisobutyrate 5.5 ± 0.6 
Transition State Analogues     




-CF3 -H -PO32– (R,S)-2,2,2-trifluoro-1-
hydroxyethylphosphonate 
(TFHEP) 
0.67 ± 0.13 
-CH3 -H -PO32– (R,S)-1-
hydroxyethylphosphonate (1-
HEP) 
40.2 ± 4.8 
aUnless indicated otherwise, values are competitive inhibition constants. Values are means of triplicate trials, 
and reported errors are the standard deviations. 
bKm values from ref 4. 
cFrom ref 5. 
dFrom ref 6. 
eFrom ref 25. 
 
Inhibition by Transition State/Intermediate Analogues 
Because trifluoromethyl groups imbued ground state analogues with higher binding affinity, we explored the 
possibility of incorporating a trifluoromethyl group into the structure of a transition state/intermediate 
analogue inhibitor. Previously, we demonstrated that (R,S)-α-hydroxybenzylphosphonate was a potent inhibitor 
of MR (Table 2).(25) Therefore, we prepared (R,S)-TFHEP as an analogue of the putative aci-carboxylate 
intermediate formed during the racemization of trifluorolactate.(4) Interestingly, MR bound (R,S)-TFHEP with an 
affinity that was only ∼2-fold greater than the affinity exhibited for TFL (Table 2), in contrast to the ∼230-fold 
higher affinity exhibited for (R,S)-α-hydroxybenzylphosphonate relative to mandelate. Although it appears that, 
in this case, the trifluoromethyl group does not make a significant contribution to the enhanced binding affinity, 
such is not the case. First, the overall binding affinity of TFHEP is expected to be reduced relative to that of α-
hydroxybenzylphosphonate because of the lower transition state stabilization energy afforded by MR during the 
racemization of the corresponding fluorinated substrate. The transition state stabilization afforded by MR when 
mandelate is the substrate is −26 kcal/mol,(2) while the transition state stabilization is reduced to −20 kcal/mol 
when TFL is the substrate.(4) Consequently, one would expect MR to bind a transition state/intermediate 
analogue based on the structure of the aci-carboxylate of TFL with approximately 2.5 × 104-fold less affinity than 
it would bind the corresponding transition state/intermediate analogue based on the structure of the aci-
carboxylate of mandelate. The observed decrease in affinity for (R,S)-TFHEP (Ki = 0.67 mM), relative to that for 
(R,S)-α-hydroxybenzylphosphonate (Ki = 4.7 μM), is in accord with this expectation, although the magnitude of 
the decrease in binding affinity (∼143-fold) is certainly much smaller than expected. Second, the nonfluorinated 
analogue of (R,S)-TFHEP, i.e., (R,S)-1-HEP, is bound with an affinity that is 60-fold lower than that exhibited for 
the corresponding fluorinated intermediate/transition state analogue. Thus, the presence of the trifluoromethyl 
group in the phosphonate-based transition state/intermediate analogue does enhance binding compared to 
that observed for the corresponding nonfluorinated analogue. Such enhanced binding arising from substitution 
of a trifluoromethyl group for a methyl group is not unexpected. For example, α-methylacyl-CoA racemase binds 
the α-methyl group of ligands at a hydrophobic pocket within the enzyme’s active site,(27, 28) and replacement 
of the α-methyl group in α-methylmyristoyl-CoA with an α-trifluoromethyl group leads to a 152-fold greater 
binding affinity.(29) 
Sructure of MR Complexed with TFHTP 
The X-ray crystal structure of wild-type MR complexed with TFHTP was determined to 1.68 Å resolution. As with 
previous crystal structures of MR, the enzyme crystallized in space group I422 and the asymmetric unit consists 
of two tightly associating monomers.(7-11) Each monomer of the stable dimer contributes residues to the 
neighboring active site, and the dimer forms the biologically active octamer through crystallographic symmetry. 
There are no significant structural changes observed for the ligand-bound structure(8) relative to the ligand-free 
structure (Figure 1A). 
 
Figure 1. Alignment of the structures of the MR–TFHTP, MR–tartronate, and tmMR–benzilate complexes with 
ligand-free MR (PDB entry 2MNR(8)). The structures of the MR–TFHTP (A), MR–tartronate (B), and tmMR–
benzilate (C) complexes exhibit no appreciable structural changes with respect to the structure of ligand-free 
MR. The root-mean-square deviation is 0.3 Å upon alignment of the Cα atoms of the biological dimer from MR–
TFHTP (monomer A, green; monomer B, cyan) and MR–tartronate (monomer A, yellow; monomer B, purple) 
complexes with the equivalent dimer from ligand-free MR (maroon). Alignment of the dimer from the tmMR–
benzilate complex (monomer A, light blue; monomer B, blue) with the equivalent dimer from ligand-free MR 
(maroon) reveals that the 20s loop of the N-terminal capping domain (green) is not closed over the active site. In 
all structures, the divalent metal ion is shown in space-filling representation (olive) and the ligands are shown in 
stick representation. 
 
The electron density for the TFHTP ligand varies between active sites, and while both active sites contain 
acceptable B factors, the electron density for the ligand is most complete for monomer B (Figure 2A). This 
discrepancy in ligand binding appears to stem from the inherent disorder associated with a segment of the N-
terminal capping domain (Asn 15–Val 35), i.e., the 20s loop, that closes over the active site, constricting the 
active site cavity and enhancing coordination of the ligand with the metal center.(12) The electron density for 
the 20s loop of monomer A is weak relative to that of monomer B, and therefore, the observed electron density 
for TFHTP is more poorly defined in the active site of monomer A. The descriptions of ligand binding are, 
consequently, limited to the active site of monomer B. 
 
Figure 2. Active site architecture of the MR–TFHTP, MR–benzilate, and tmMR–benzilate complexes. 
Representative simulated annealing omit maps for the Mg2+–TFHTP (A) and Mg2+–tartronate (B) complexes in 
the active site of MR and the Mg2+–benzilate complex in tmMR (C) are shown. The electron density maps are 
contoured at 3.0σ and extend to a distance of 5 Å from the ligand. (D) A stereoview shows the close packing of 
the trifluoromethyl groups of TFHTP within the hydrophobic cavity of the active site of MR. The two active site 
Brønsted acid–base catalysts Lys 166 and His 297, Mg2+ (labeled M), water (labeled W), and TFHTP are shown in 
space-filling representation (with carbon, oxygen, nitrogen, fluorine, and Mg2+ atoms colored cyan, red, blue, 
“limon”, and gray-green, respectively). Hydrophobic residues are shown in stick representation, including Leu 93 
from the adjacent subunit within the dimer (green). The purple contour shows the van der Waals surface of the 
hydrophobic residues. (E) A stereoview shows the superposition of the structures of the MR complexes with 
bound benzohydroxamate (BzH, purple; PDB entry 3UXK(12)), TFHTP (green), and tartronate (orange). The 
Mg2+ ion is shown in space-filling representation, while the ligands and Asn 197, His 297, and Lys 166 are shown 
in stick representation. Putative hydrogen bonds are shown as dashes, and the measurements are in angstroms. 
 
TFHTP does not bind in the expected “catalytic” orientation, with the glycolate moiety chelating the Mg2+ ion as 
observed previously in the complexes of MR with (S)-mandelate and (S)-atrolactate.(7, 9-11) Instead, TFHTP 
interacts indirectly with the active site Mg2+ through a bridging water molecule (Figure 2A). The surprisingly high 
binding affinity of TFHTP must, therefore, arise for reasons other than its ability to chelate the active site metal 
ion. First, the two trifluoromethyl groups are intimately packed within the hydrophobic pocket, packing against 
residues of the closed active site flap (Leu 18, Val 22, Thr 24, and Val 29), residues within the α/β-barrel (Phe 52 
and Tyr 54), Leu 298 (on a loop between the strand β10 and α-helix(8)), residues at the end of the β11 strand 
(Leu 319 and Leu 321), and Leu 93 from the adjacent monomer within the dimer (Figure 2D). Second, the 
carboxylate group is locked in place by several H-bonds (Figure 2E). Asn 197 and Lys 166 form H-bonds ∼3.2 Å in 
length to one oxygen of the carboxylate. Nε2 of His 297 interacts with the other oxygen of the carboxylate group 
via an H-bond of 2.6 Å, and Glu 317 interacts with the same carboxylate oxygen via a bridging water molecule 
(not shown). Thus, rather than chelating the Mg2+ ion, the carboxylate of TFHTP forms a bridge between the two 
active site Brønsted acid–base catalysts His 297 and Lys 166. As a consequence of its binding orientation, the 
carboxylate group assumes a binding orientation such that the plane of the carboxylate group is roughly 
perpendicular to the orientation of the hydroxamate moiety of BzH (Figure 2E). In addition, Nε2 of His 297 
interacts with the α-OH group of TFHTP via an H-bond of 3.3 Å. Considering that the pKa of the hydroxyl group of 
TFHTP should be markedly reduced relative to that of aliphatic alcohols (pKa values are 17.1 for 2-
propanol(30) and 9.3 for hexafluoro-2-propanol,(31) bearing in mind that a hydrophobic environment may 
increase the pKa from that expected in aqueous solution), it is plausible that the enhanced binding of TFHTP may 
also arise, in part, from the transfer of the proton from the hydroxyl group to His 297. Such a scenario is 
reminiscent of the time-of-flight neutron structure of the d-xylose isomerase–product complex reported by 
Langan and co-workers(32) in which O5 of d-xylulose was not protonated but formed an H-bond (3.07 Å) with a 
doubly protonated His residue. Hence, it is the effect of the optimal hydrophobic packing interactions “pulling” 
the trifluoromethyl groups of TFHTP toward the active site flap, the steric bulk of the trifluoromethyl groups that 
resides outside the plane of the phenyl ring of BzH, and the bridging interactions between the active site bases 
that produce the higher binding affinity of TFHTP even though the glycolate moiety failed to chelate the 
Mg2+ ion. Consequently, the Mg2+ ion is coordinated by a water molecule (Figure 2A) rather than the α-OH group 
and carboxylate of TFHTP. 
Inhibition by Tartronate 
Recognizing that binding of a ligand could be enhanced when a ligand positions a carboxylate between the 
active site Brønsted acid–base catalysts, we anticipated that tartronate might be an inhibitor of MR. Tartronate 
is a structural mimic of mandelate in which the glycolate moiety is retained but the phenyl ring is replaced with 
a carboxylate group (Scheme 1). Interestingly, tartronate inhibited MR with a binding affinity that was similar to 
that observed for mandelate (Table 2), despite having the polar carboxylate group in place of the nonpolar 
phenyl ring. In fact, the 15–18-fold difference in binding affinities between lactate and tartronate reveals that 
the carboxylate group of tartronate contributes an additional 1.7 kcal/mol in binding energy relative to the 
methyl group of lactate. This observation suggests that inhibition by tartronate does indeed arise, in part, 
through interaction of the carboxylate with the active site Brønsted acid–base catalysts. 
Structure of MR Complexed with Tartronate 
The X-ray crystal structure of wild-type MR complexed with tartronate was determined to 1.80 Å resolution. 
Unlike TFHTP, tartronate is bound in a substratelike orientation, with the glycolate moiety chelating the Mg2+ ion 
in the active site (Figure 2B). As predicted, the second carboxylate group bridges the two active site Brønsted 
acid–base catalysts. The carboxylate oxygens of tartronate are positioned 2.7 Å from His 297 and 4.0 Å from Lys 
166 (Figure 2E). Interestingly, in all of the ligand-bound structures of MR, Lys 166 assumes an identical rotamer, 
irrespective of the identity of the bound ligand or the H-bonding potential with different functional groups on 
these ligands (Figure 2E). Nevertheless, the structure supports our hypothesis that the greater than expected 
binding affinity of tartronic acid results from the interaction of the second carboxylate group with the two 
Brønsted acid–base catalysts. 
While the α-carbon of tartronic acid is not a stereogenic center, the electron densities observed for the ligands 
in monomers A and B of the structure of MR cocrystallized with tartronate suggest that the ligand binds in the 
active site in two opposing orientations (Figure 3). The bound tartronate in monomer B is best modeled with the 
α-carbon in the position that would be occupied by the α-carbon of (S)-mandelate, while in monomer A, the 
bound tartronate is best modeled with the α-carbon in the position that we anticipate would be occupied by the 
α-carbon of (R)-mandelate (Figure 3A,B). The orientation of tartronate in monomer A, therefore, may offer 
insight into how (R)-mandelate is oriented in the active site, because all attempts to cocrystallize MR with (R)-
mandelate or (R)-mandelate analogues have, thus far, been unsuccessful or have caused crystals to crack in 
soaking-in experiments (unpublished observations). An overlay of chains A and B, centered on the active site, 
reveals the difference in the α-carbon position adopted by tartronate in the two active sites (Figure 3C). The 
difference in the α-carbon position is consistent with our previous conclusions that the positions of the 
functional groups chelating Mg2+ remain relatively fixed during catalysis and that the α-carbon and phenyl group 
move during racemization.(6, 12) The two Brønsted acid–base catalysts His 297 and Lys 166 occupy identical 
positions in these two active sites (Figure 3C). However, exclusively in monomer A where the α-carbon of 
tartronate mimics the (R)-mandelate orientation, there are two conformations for the 20s loop that forms part 
of the hydrophobic cavity within the active site. The 20s loop of monomer A adopts both the open and closed 
conformations, each at 50% occupancy, while the 20s loop in monomer B fully occupies the closed conformation 
(Figure 3D). The difficulties associated with cocrystallizing and/or soaking the enzyme with (R)-mandelate or 
corresponding analogues suggest that there may be considerable conformational changes associated with the 
binding of the substrate in the R stereochemistry. 
 
Figure 3. Tartronate and benzilate bound in the active site. Bound tartronate in monomer A (A) and monomer B 
(B) are shown with electron density maps contoured at 3.0σ, and extending to a distance of 5 Å from each 
ligand. The orientation of tartronate in monomer A may mimic that of (R)-mandelate, while the orientation of 
tartronate in monomer B mimics that of (S)-mandelate. (C) An overlay of bound tartronate in monomers A 
(green) and B (yellow), centered on the active site, shows the distances between the α-carbon and His 297 and 
Lys 166, and (D) an expanded view shows the two conformations adopted by the 20s loop upon tartronate 
binding. In monomer A, the 20s loop adopts both an open (light green) and a closed (green) conformation, while 
in monomer B, the 20s loop has a closed conformation (yellow). (E) A stereoview shows the superposition of the 
structures of the MR–tartronate (monomer A) and tmMR–benzilate complexes. The 20s loop of the tmMR–
benzilate complex (cyan) adopts an open conformation, similar to that of the 20s loop in monomer A of the MR–
tartronate complex [light green; cf. the closed conformation (green)]. The Brønsted acid–base catalysts Lys 166 
and His 297 are shown in stick representation, and Mg2+ (green) and a water molecule (red) are shown in space-
filling representation. 
 
Structure of the tmMR–Benzilate Complex 
As mentioned above, structures of MR with (R)-mandelate or (R)-mandelate analogues are not yet available; 
hence, “snapshots” of the entire reaction catalyzed by MR are also not available. We reasoned that benzilate, a 
substrate-product analogue,(6) might be more amenable to crystallization and would provide insights into the 
orientation and position of the aromatic rings corresponding to both (R)- and (S)-mandelate, recognizing, of 
course, that the 7.128 Å separation between the para carbon atoms of the phenyl rings observed in the crystal 
structure of potassium benzilate(33) probably exceeds the distance that the para carbon atom of mandelate 
moves during MR-catalyzed racemization (∼1.6–2.4 Å) and that the ipso carbon remains relatively fixed during 
MR-catalyzed racemization.(6, 12) Unfortunately, despite several cocrystallization and soaking experiments, we 
were unable to obtain the structure of benzilate within the active site of wild-type MR, possibly because the 
hydrophobic pocket cannot accommodate two aromatic rings in a conformation that remains amenable to 
crystallization. However, as part of our ongoing studies of MR, we had prepared the C92S/C264S/K166C triple 
mutant of MR (tmMR). We anticipated that truncation of the side chain of Lys 166 might afford additional room 
in the active site, permitting benzilate to bind in a catalytically relevant orientation. The X-ray crystal structure of 
tmMR complexed with benzilate was determined to 1.89 Å resolution. As observed for the previously described 
wild-type structures, tmMR crystallized in space group I422 with the asymmetric unit consisting of two 
monomers associating as a biological dimer. The overall structure of tmMR remains largely unperturbed when it 
is aligned with the ligand-free structure (Figure 1C). 
As predicted, the removal of the side chain of Lys 166 in tmMR permitted benzilate to bind in a substratelike 
orientation similar to that of tartronate and the substrate analogue (S)-atrolactate (Scheme 1),(9) chelating the 
catalytic Mg2+ ion with the α-hydroxyl oxygen and one of the carboxylate oxygens. The 20s loop of the N-
terminal capping domain could be modeled for only monomer A because the observed electron density for this 
region in monomer B was irregular and discontinuous, suggesting multiple conformations. Interestingly, the 20s 
loop of the N-terminal capping domain of monomer A occupies the same open conformation that was observed 
in monomer A of the MR–tartronate structure described above (Figures 1C and 3E). Considered together, the 
structures of MR described in this study suggest that the conformation of the 20s loop depends on two features 
that are expected to be unique to (R)-mandelate: the position of the α-carbon and the position of the aromatic 
ring. Specifically, when a ligand positions its α-carbon and α-proton like those of (R)-mandelate (i.e., tartonate in 
monomer A of wild-type MR) or its aromatic ring in a position expected to be similar to that of (R)-mandelate 
(i.e., one of the two aromatic rings of benzilate in tmMR), the 20s loop adopts a more open conformation 
(Figure 3E). Thus, the 20s loop of MR likely undergoes a significant conformational change upon binding (R)-
mandelate. 
Conclusions 
At first blush, it is unlikely that one would conceive of either TFHTP or tartronate as an inhibitor of MR. However, 
our observations that MR can bind TFL as a substrate with an affinity similar to that exhibited for 
mandelate(4) and that MR is capable of also binding the substrate-product analogue benzilate with a similar 
affinity(6) led us to anticipate that MR might be inhibited by TFHTP. The fact that TFHTP was bound only 3-fold 
less tightly than the most potent transition state analogue inhibitors reported to date led us to examine the X-
ray crystal structure of the MR–TFHTP complex, which revealed an unexpected binding orientation. The high 
binding affinity of TFHTP arises from efficient packing of the two trifluoromethyl groups within the hydrophobic 
pocket of the enzyme’s active site and through the participation of the carboxylate group in a bridge between 
the two active site Brønsted acid–base catalysts His 297 and Lys 166. This observation suggests that inhibitors 
may be designed to capitalize on the recognition of the active site Brønsted acid–base catalysts as binding 
determinants, as we showed for tartronate. Consequently, this inhibitor design strategy should allow the 
development of inhibitors of other enzymes of the enolase superfamily, such as those in the MR, MLE, and MAL 
subgroups.(34-36) 
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